Xiaoang Yang

Prof. Xiaoang Yang


Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2012 in Antiviral Therapy
Verified
Journal Article
Open access
YZYubing Zhou
Yubing Zhou
YZYan Zhang
Yan Zhang
XYXiaoang Yang
Xiaoang Yang
JZJing Zhao
Jing Zhao
LZLiyun Zheng
Liyun Zheng
JCJunbiao Chang
Junbiao Chang
Background: HBV infection causes major public health problems worldwide. The clinical limitation of current antiviral drugs for HBV, such as lamivudine, is causing rapid emergence of drug-resistant viral strains during prolonged antiviral therapy. Therefore, new antiviral drugs are urgently needed to prevent or delay the selection of drug-resistant HBV mutants. A novel cytidine analogue, FNC (2′-deoxy-2′-β-fluoro-4′-azidocytidine), was recently shown to strongly inhibit human HBV and duck HBV (DHBV) replication in vitro and in vivo, respectively. The present study was designed to evaluate the in vitro antiviral activity of FNC against clinical wild-type and lamivudine-resistant HBV isolates in transiently transfected cells. Methods: HBV DNA was extracted from serum samples collected both before lamivudine therapy and at the time of viral breakthrough and was amplified by PCR. The amplicon was cloned into a novel expression vector, pHY106, which can initiate the intracellular HBV replication cycle after cell transfection. Following transfection of the cloned amplicon into HepG2 cells, a drug susceptibility assay was performed. Quantitative real-time PCR was used for determining the amount of intracellular HBV DNA, and the effective concentration required to reduce HBV replication by 50% (EC 50 ) was calculated. Results: FNC inhibited the replication of both wild-type and lamivudine-resistant HBV clinical isolates in a dose-dependent manner, with mean ±sd EC 50 values of 0.12 ±0.01 μM and 0.27 ±0.01 μM, respectively. Conclusions: FNC is a potential antiviral agent against both wild-type and lamivudine-resistant HBV clinical isolates, and therefore deserves further evaluation for the treatment of HBV infection.

26 October 2018 in Journal of Cellular Physiology
Verified
Journal Article
Closed access
PDF file
LGLili Ge
Lili Ge
QWQinglei Wang
Qinglei Wang
SHShengnan Hu
Shengnan Hu
XYXiaoang Yang
Xiaoang Yang

26 October 2018 in Journal of Cellular Biochemistry
Verified
Journal Article
Closed access
PDF file
LGLili Ge
Lili Ge
XZXianwei Zhang
Xianwei Zhang
SHShengnan Hu
Shengnan Hu
YSYinsen Song
Yinsen Song
JKJinghui Kong
Jinghui Kong
XYXiaoang Yang
Xiaoang Yang